Expert consensus on treatment for stage III non‐small cell lung cancer-Reference-Cited by-同舟云学术

Expert consensus on treatment for stage III non‐small cell lung cancer

Published:2023-03 Issue:1 Volume:1 Page:3-13
ISSN:2834-443X
Container-title:Medicine Advances
language:en
Short-container-title:Medicine Advances

Author:

Wu Yi‐Long¹²,Lu Shun³,Zhou Qinghua⁴,Zhang Li⁵,Cheng Ying⁶,Wang Jie⁷,Wang Buhai⁸,Hu Chengping⁹,Lin Lizhu¹⁰,Zhong Wenzhao¹,Song Yong¹¹,Yang Nong¹²,Dong Xiaorong¹³,Zhao Jian¹⁴,Yang Haihong¹⁵,Guo Hui¹⁶,Yan Xiaolong¹⁷,Liu Hongxu¹⁸,Ma Rui¹⁸,Lin Jie¹⁹,Liu Siyang¹,Chen Chun²⁰,Wang Lifeng²¹,Zhou Chengzhi¹⁵,Zhou Ming¹⁴,Wu Fang²²,Yang Xue‐Ning¹,Du Yingying²³,Yao Yu¹⁶,Shao Yang²⁴,Hong Shaodong⁵,Cui Jiuwei²⁵,Quan Xueping²⁶,Chen Rongrong²⁷,Wu Jiayan²⁸,Zhang Jiatao¹,Zhou Jianya²⁹,Wang Binchao¹,Cheng Chao³⁰,Wang Huijuan³¹,Liu Jingjing⁶,Wu Lin¹²,Huang Yan⁵,Kuang Yukun³⁰,Zhang Yongchang¹²,Hu Jia³²,Yang Jinji¹,Feng Weineng³³,Su Wenmei³⁴,Fan Yun³⁵,Yang Fan³⁶,Chen Ming⁵,Tang Kejing³⁰,Pan Yi¹,Shen Peng³⁷,Liu Anwen³⁸,Zhang Haibo³⁹,Liang Wenhua¹⁵,Zhou Qing¹,Ma Zhiyong³¹,Cai Xiuyu⁵,Liu Hui⁵,Chen Longfei⁴⁰,Chuai Shaokun⁴⁰,Shan Jianzhen²⁹,Zheng Yanfang¹⁴,You Changxuan³⁷,Zhu Xiaoxia⁴¹,Li Li⁴²,Zhang Tongmei⁴³,Tu Haiyan¹,Lin Wurong⁴⁴,Zhang Xuchao¹,Zhou Penghui⁵,Ke Zunfu³⁰,Liang Huiying¹

Affiliation:

1. Guangdong Lung Cancer Institute Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China

2. Chinese Association of Lung Cancer (CALC) Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) Guangzhou China

3. Shanghai Chest Hospital Shanghai Jiaotong University Shanghai China

4. Lung Cancer Institute/Lung Cancer Center West China Hospital Sichuan University Chengdu Sichuan China

5. Sun Yat‐sen University Cancer Center Guangzhou Guangdong China

6. Jilin Cancer Hospital Changchun Jilin China

7. Cancer Hospital Chinese Academy of Medical Sciences Beijing China

8. Subei People's Hospital Affiliated to Yangzhou University Yangzhou Jiangsu China

9. Xiangya Hospital of Central South University Changsha Hunan China

10. The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine Guangzhou Guangdong China

11. Jinling Hospital of Nanjing University School of Medicine Nanjing China

12. Department of Medical Oncology Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China

13. Union Hospital Affiliated to Tongji Medicine College of Huazhong University of Science and Technology Wuhan Hubei China

14. Affiliated Cancer Hospital & Institute of Guangzhou Medical University Guangzhou Guangdong China

15. The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China

16. The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shanxi China

17. Department of Thoracic Surgery Tangdu Hospital The Air Force Military Medical University Xi'an China

18. Liaoning Cancer Hospital & Institute Shenyang Liaoning China

19. The Second Affiliated Hospital of Kunming Medical University Kunming Yunnan China

20. Fujian Medical University Union Hospital Fuzhou Fujian China

21. The Affiliated Drum Tower Hospital of Nanjing University Medicine School Nanjing Jiangsu China

22. The Second Xiangya Hospital of Central South University Changsha Hunan China

23. The First Affiliated Hospital of Anhui Medical University Hefei China

24. Geneseeq Technology Inc. Nanjing Jiangsu China

25. The First Bethune Hospital of Jilin University Changchun Jilin China

26. Shanghai Tongshu Biotechnology Co., Ltd. Shanghai China

27. Beijing GenePlus Technology Co., Ltd. Beijing China

28. Berry Oncology Co., Ltd Fuzhou Fujian China

29. The First Affiliated Hospital of College of Medicine of Zhejiang University Hangzhou Zhejian China

30. The First Affiliated Hospital of Sun Yat‐sen University Guangzhou Guangdong China

31. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou China

32. Zhongshan Hospital Affiliated to Fudan University Shanghai China

33. The First People's Hospital of Foshan Foshan Guangdong China

34. Affiliated Hospital of Guangdong Medical University Zhanjiang Guangdong China

35. Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital Hangzhou Zhejiang China

36. Peking University People's Hospital Beijing China

37. Nanfang Hospital of Southern Medical University Guangzhou Guangdong China

38. The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi China

39. Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong China

40. Guangzhou Burning Rock Biotech Co., Ltd. Guangzhou Guangdong China

41. Zhujiang Hospital of Southern Medical University Guangzhou Guangdong China

42. Daping Hospital of Army Medical University Chongqing China

43. Department of Medical Oncology Beijing Chest Hospital Capital Medical University Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing China

44. OrigiMed Shanghai Co., Ltd. Shanghai China

Abstract

AbstractStage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation with a multiple disciplinary team, which allows the development of a proposal for clinical diagnosis and treatment. In this consensus, stage III NSCLC is divided into two types (operable and inoperable) according to different clinical conditions. Resectable NSCLC is further subdivided into two conditions (with or without driver genes). For each clinical scenario, this consensus emphasizes that the foundation of any medical decisions regarding the optimal diagnostic or therapy procedure is scientific evidence from clinical research. Finally, based on the level of evidence and strength of recommendations, this consensus provides recommendations for the management of stage III NSCLC from six perspectives. The objective of this consensus is to help clinicians choose the best treatment and promote the standardization of stage III NSCLC diagnosis and treatment in China.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/med4.7

Reference51 articles.

1. National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of care

2. Stage at diagnosis and early mortality from cancer in England

3. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy

4. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study;Signal Transduction and Targeted Therapy;2024-06-14

2. Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery;Heliyon;2023-11